Smart Targeted Drug Delivery

Creating a new standard of care for the treatment and mitigation of tumor-based cancers.

Sensor-Kinesis Logo
Cognos Therapeutics Inc. (Cognos) is an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases including tumor-based brain and spinal cancers, degenerative cognition disorders (such as Alzheimer’s and Parkinson’s disease), cerebral trauma occurrences (such as epilepsy and stroke) as well as other Central Nervous System afflictions.

Cognos’ initial focus is on cancer treatment, in which localized chemotherapeutic and immunotherapeutic agents are delivered via an implantable pump which is capable of providing targeted, metronomic delivery of patient-specific chemotherapeutics directly into a tumor site. In addition, the pump, currently called the iPsum-g1, is also capable of providing real-time diagnostic and biologic environment data directly to the treating physician in order to allow for monitoring and adjustment of treatment at anytime from anywhere in the world.

 

This technology will change the standard of care for low-survival rate tumor-based cancers, such as leptomeningeal carcinoma, by moving the battle against these diseases from systemic, global treatment to a targeted site-specific modality where efficacy of treatment has a much higher success factor.

Visit Cognos Therapeutics
Cognos Therapeutics has proposed a variety of potential product candidates for its Smart Drug Delivery System technology including the following:

iPsum-g1™
The pre-commercialized iPsum-g1™ is an implantable pump that enables delivery of medications to a targeted area in microliter resolutions at precisely scheduled intervals based on a patients’ personal responses to the therapy and tolerance to the drug dose. Additionally, efficacy of treatment is monitored through an on-board biosensor that is able to translate biological areas of interest relevant to the disease and translate this data into digital information that can be tracked in real-time by the treating physician in order to allow for remote adjustment of dose and frequency as needed.
LEARN MORE
The Cognos iPsum-g1 technology provides the following benefits:

  • Implantable pump
  • Targeted local delivery of therapeutics through a dual-lumen catheter
  • Programmable metronomic dose scheduling
  • Delivery of combinatorial and multi-need therapeutics from a single device
  • Proprietary biosensor sampling of relevant biomarker levels
  • Real-time monitoring of system and treatment efficacy
  • Secure wireless control through MICS wireless radio data communication
  • Microfluidic Card containing fluid channels
  • Refillable reservoir access via silicone septa
The iPsum-g1’s initial focus will be on the treatment of tumor-based cancers of the brain and central nervous system. Leptomeningeal Carcinoma (LC) was selected as the first disease model for the iPsum-g1. Using currently available treatments, the life expectancy for patients with LC is only six months. Each year, approximately 132,000 LC patients in Europe and the U.S. are diagnosed with this life-threatening disease and would be candidates for iPsum-g1 treatment.

Other areas of treatment the iPsum-g1 will address include:

  • Meningiomas
  • Gliomas
  • Glioblastomas
  • Astrocytomas
  • Pancreatic cancer
  • Ovarian cancer
  • Breast cancer
CONTACT COGNOS THERAPEUTICS

6053 W Century Blvd. Suite 1000
Los Angeles, CA 90045-6400
T: 310-641-2700
F: 310-641-2702
E: info@cognosthx.com